Pushing stem cells to market  by Gross, Michael
Current Biology Vol 15 No 15
R576
Merlin the wizard is a well-known
figure from ancient Celtic
legends, who was later recruited
to the Arthurian circle as a
teacher of young Arthur and as
the magic power behind the
throne. Thus it is no surprise that
Welsh-born ‘serial company
founder’ (in his own words) and
multiple biotech entrepreneur
Chris Evans chose the name
Merlin when he set up a seed
capital firm in 1996, moving on
from founding and leading his
own biotech companies to a role
involving nurturing new
companies and pulling strings
behind the scenes. By now,
Evans has become ‘Sir
Christopher’, and Merlin
Biosciences Ltd. has invested in
24 flourishing biotech companies
in Europe, making it the biggest
biotech investor in Europe
(www.merlin-biosciences.com). 
Now the Welsh wizard is set to
apply his magic to the field of
stem-cell-based therapies, which
most investors have so far been
reluctant to touch even with a
very long wand. Merlin
Biosciences is seeking to
relaunch its company ReNeuron
on the Alternative Investments
Market (AIM) of the London Stock
Exchange. 
The company’s short history
highlights the difficulty of setting
up companies in this young field.
Founded in 1997 with seed
capital from Merlin, it was first
listed at the stock exchange in
2000, as the first European stem
cell company. But after the
scientific and economic fortunes
of the company faltered, Evans
paid out the other shareholders
and took the company private
again in 2003. 
Since then, the company
claims to have made significant
progress on the scientific front.
Its key asset is a patented
technology based on the c-myc
gene, whereby neural stem cells
can be multiplied in culture
indefinitely, but stopped from
growing by withdrawal of a
chemical signal. Using this
approach in cell therapy of stroke
models, ReNeuron has obtained
promising pre-clinical data, and is
hoping to start clinical trials in
either the UK or the US early next
year. It has also broadened its
development pipeline by starting
programs to address type I
diabetes, Parkinson’s disease,
Huntington’s disease, and eye
disorders. It has also signed a
deal with the US company
StemCells Inc., under which both
companies mutually benefit from
each other’s technologies.
The fact that the whole
science base is still early
stage and insecure is a
fundamental problem for
all who want to set up
companies in this field.
Some of the visionary
proposals of ‘therapeutic
cloning,’ including the
growth of replacement
tissues from stem cells
specifically generated for
each patient, may not be
mass-compatible at all.
Thus Evans feels that the time
is right to go public again, and
the company announced on July
12 that it seeks £10 million from
its second appearance at the
AIM. Apart from the improved
maturity of the company’s
science base, this decision may
also have something to do with
the growing competition from
other stem cell start-ups. 
Observers have pointed to the
slow climate change in favour of
stem cell research in the US,
highlighted by the success of
Proposition 71 in California. In
press interviews, Evans has
hinted that the current re-listing
of ReNeuron on the AIM may be
his last attempt to keep the
company in the UK. Should it fail
to drum up the required funds, he
might decide to move ReNeuron
across the Atlantic. 
That the AIM listing might fail
to come up with the desired cash
was demonstrated
simultaneously by the
announcement of the Scotland-
based Stem Cell Sciences, which
announced that it had only raised
£5.6 million instead of the £10
million hoped for with its AIM
listing. Founded by Peter
Mountford, who moved back and
forth between Melbourne and
Edinburgh, Stem Cell Sciences
has R&D centres in Australia,
Scotland and Japan, and plans to
expand to the US. 
While to state-funded
academic stem cell researchers
the grass is definitely greener in
the UK than in the US, the reverse
impression may arise for those in
stem cell companies. In contrast
to the two British outfits
struggling to raise 8-figure sums
from the AIM, there are several
US-listed companies that have a
zero more on their valuation sum.
These include the pioneering
Geron, founded in 1992, which
originally held intellectual
property rights to many of the
stem cell lines developed at the
University of Wisconsin, Aastrom
Biosciences Inc. from Ann Arbor,
Michigan, and ReNeuron’s
collaboration partner StemCells
Inc. from Palo Alto, California.
And following the passage of
Proposition 71 in California,
which promises up to $3 billion
for stem cell research, there have
been reports of intense
headhunting for the top
researchers in the field. 
But California is not the only
land of opportunity. Favourable
conditions for stem cell
companies are also found in
Singapore for instance, where
Alan Colman, of Dolly fame, and
his company ES Cell International
(ESI) have just moved into the
brand new Biopolis research
centre. Founded in 2000, the
company hit it lucky a year later,
when it found itself in possession
of some of the very few stem cell
lines approved for research by
the US government. Under
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Colman’s leadership, the
company has focused on the
development of cell therapies, a
proposal made possible by
funding from Singapore’s
government and from Australian
investors. 
Australia, too, boasts a few
stem cell companies listed on the
Australian stock exchange, even
though these tend to be very
early stage. Experts have
described this phenomenon as a
characteristic of the Australian
Stock Exchange: it tends to list
companies earlier than other
markets, often before clinical
trials. 
The fact that the whole science
base is still early stage and
insecure is a fundamental
problem for all who want to set
up companies in this field. Some
of the visionary proposals of
‘therapeutic cloning’, including
the growth of replacement
tissues from stem cells
specifically generated for each
patient, may not be mass-
compatible at all. All therapies
which are derived from a
patient’s own cells will be difficult
to assess in traditional clinical
trials, as each treatment will be
different, and may turn out to be
extremely expensive. 
Academic researchers at
Oxford University led by Herman
Waldmann and Paul Fairchild are
developing a method to make cell
therapies immunologically
compatible to large numbers of
patients, but they estimate that it
could take more than a decade
before such generally usable ‘off
the shelf’ cell therapeutics might
reach the clinic. So it may just be
too early to raise great hopes for
patients or investors in this field. 
“The mixed fortunes of
companies like Stem Cell
Sciences may reflect the
ambivalence of the general public
towards stem cell biology: while
the therapeutic benefits for the
treatment of intractable diseases
are evident to all, the journey to
the clinic is far from
straightforward, making it difficult
to realise returns on investments
in the short-term,” says Fairchild.
Additionally, the wildly
contradictory stem cell legislation
across Europe and even between
different states of the US implies
that even if a company had a
clinically proven stem cell
therapy to sell today, they might
find it very difficult to bring it to
the market, or to arrange a deal
with a major pharmaceutical
company, who would want to
avoid such difficulties. 
Where does this leave the two
British companies struggling for
their funding? In spite of the very
positive support of stem cell
research by the UK government,
the market introduction of Stem
Cell Sciences has shown that
investors are very cautious about
such companies, due to all the
scientific and political problems
mentioned above. Maybe
ReNeuron will need a bit more of
Merlin’s magic before things start
happening. And in spite of all the
legislative support for stem cell
research in the UK and some
other countries, moving research
findings on towards a business
might be more easily carried out
elsewhere.
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Moving on: Entrepreneurs are keen to back stem cell research but the climate of support is more favourable in the US than in Europe.
A lab worker at the Massachusetts Institute of Technology (Photo: Sam Ogden/Science Photo Library).
